nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—Ibuprofen—Procarbazine—brain cancer	0.399	1	CrCrCtD
Naproxen—CYP2C9—brain cancer	0.323	1	CbGaD
Naproxen—UGT1A1—Etoposide—brain cancer	0.0463	0.295	CbGbCtD
Naproxen—CYP1A2—Carmustine—brain cancer	0.0354	0.225	CbGbCtD
Naproxen—PTGS2—Etoposide—brain cancer	0.0278	0.177	CbGbCtD
Naproxen—PTGS1—Etoposide—brain cancer	0.0235	0.15	CbGbCtD
Naproxen—CYP2C8—Etoposide—brain cancer	0.0136	0.0863	CbGbCtD
Naproxen—CYP1A2—Etoposide—brain cancer	0.0105	0.0668	CbGbCtD
Naproxen—AKR1C3—Podofilox—Etoposide—brain cancer	0.00204	1	CbGdCrCtD
Naproxen—Agomelatine—CYP2C9—brain cancer	0.000678	0.264	CrCbGaD
Naproxen—Suprofen—CYP2C9—brain cancer	0.000588	0.229	CrCbGaD
Naproxen—Indomethacin—CYP2C9—brain cancer	0.000374	0.146	CrCbGaD
Naproxen—Flurbiprofen—CYP2C9—brain cancer	0.000331	0.129	CrCbGaD
Naproxen—Ketoprofen—CYP2C9—brain cancer	0.000299	0.117	CrCbGaD
Naproxen—Ibuprofen—CYP2C9—brain cancer	0.000294	0.115	CrCbGaD
Naproxen—CYP1A2—Xenobiotics—CYP2C9—brain cancer	0.000243	0.0145	CbGpPWpGaD
Naproxen—UGT1A1—Irinotecan Pathway—APC—brain cancer	0.000234	0.014	CbGpPWpGaD
Naproxen—CYP1A2—Tamoxifen metabolism—CYP2C9—brain cancer	0.000234	0.0139	CbGpPWpGaD
Naproxen—AKR1C3—Metapathway biotransformation—CYP2C9—brain cancer	0.000219	0.0131	CbGpPWpGaD
Naproxen—PTGS2—Arachidonic acid metabolism—CYP2C9—brain cancer	0.000206	0.0123	CbGpPWpGaD
Naproxen—PTGS1—ganglion—brain cancer	0.000195	0.0482	CbGeAlD
Naproxen—PTGS1—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000182	0.0109	CbGpPWpGaD
Naproxen—AKR1C3—pituitary gland—brain cancer	0.000173	0.0428	CbGeAlD
Naproxen—PTGS1—endothelium—brain cancer	0.000168	0.0416	CbGeAlD
Naproxen—CYP2C8—Arachidonic acid metabolism—CYP2C9—brain cancer	0.000168	0.01	CbGpPWpGaD
Naproxen—AKR1C3—medulla oblongata—brain cancer	0.000167	0.0413	CbGeAlD
Naproxen—PTGS2—endothelium—brain cancer	0.000161	0.0397	CbGeAlD
Naproxen—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.000159	0.00948	CbGpPWpGaD
Naproxen—PTGS1—blood vessel—brain cancer	0.000155	0.0383	CbGeAlD
Naproxen—AKR1C3—midbrain—brain cancer	0.000153	0.0378	CbGeAlD
Naproxen—AKR1C3—spinal cord—brain cancer	0.000149	0.0368	CbGeAlD
Naproxen—Insomnia—Procarbazine—brain cancer	0.000149	0.00155	CcSEcCtD
Naproxen—PTGS2—blood vessel—brain cancer	0.000148	0.0366	CbGeAlD
Naproxen—Paraesthesia—Procarbazine—brain cancer	0.000148	0.00154	CcSEcCtD
Naproxen—Hepatobiliary disease—Temozolomide—brain cancer	0.000147	0.00154	CcSEcCtD
Naproxen—Sinusitis—Temozolomide—brain cancer	0.000146	0.00153	CcSEcCtD
Naproxen—Somnolence—Procarbazine—brain cancer	0.000146	0.00152	CcSEcCtD
Naproxen—UGT2B7—Biological oxidations—CYP2C9—brain cancer	0.000146	0.00871	CbGpPWpGaD
Naproxen—Cramp muscle—Etoposide—brain cancer	0.000146	0.00152	CcSEcCtD
Naproxen—Toxic epidermal necrolysis—Etoposide—brain cancer	0.000146	0.00152	CcSEcCtD
Naproxen—UGT2B7—endocrine gland—brain cancer	0.000145	0.036	CbGeAlD
Naproxen—Haemoglobin—Carmustine—brain cancer	0.000145	0.00152	CcSEcCtD
Naproxen—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000145	0.00865	CbGpPWpGaD
Naproxen—Haemorrhage—Carmustine—brain cancer	0.000145	0.00151	CcSEcCtD
Naproxen—Ill-defined disorder—Hydroxyurea—brain cancer	0.000145	0.00151	CcSEcCtD
Naproxen—UGT2B7—Metapathway biotransformation—CYP2C9—brain cancer	0.000144	0.00859	CbGpPWpGaD
Naproxen—Anaemia—Hydroxyurea—brain cancer	0.000144	0.0015	CcSEcCtD
Naproxen—Hallucination—Carmustine—brain cancer	0.000144	0.0015	CcSEcCtD
Naproxen—CYP2C8—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000143	0.00854	CbGpPWpGaD
Naproxen—Decreased appetite—Procarbazine—brain cancer	0.000143	0.00149	CcSEcCtD
Naproxen—Oedema peripheral—Carmustine—brain cancer	0.000143	0.00149	CcSEcCtD
Naproxen—Connective tissue disorder—Carmustine—brain cancer	0.000142	0.00148	CcSEcCtD
Naproxen—Fatigue—Procarbazine—brain cancer	0.000142	0.00148	CcSEcCtD
Naproxen—Haemoglobin—Temozolomide—brain cancer	0.000141	0.00147	CcSEcCtD
Naproxen—Malaise—Hydroxyurea—brain cancer	0.00014	0.00147	CcSEcCtD
Naproxen—Pain—Procarbazine—brain cancer	0.00014	0.00147	CcSEcCtD
Naproxen—Constipation—Procarbazine—brain cancer	0.00014	0.00147	CcSEcCtD
Naproxen—Haemorrhage—Temozolomide—brain cancer	0.00014	0.00146	CcSEcCtD
Naproxen—Hepatitis—Temozolomide—brain cancer	0.00014	0.00146	CcSEcCtD
Naproxen—Dysphagia—Etoposide—brain cancer	0.00014	0.00146	CcSEcCtD
Naproxen—Leukopenia—Hydroxyurea—brain cancer	0.000139	0.00146	CcSEcCtD
Naproxen—Visual impairment—Carmustine—brain cancer	0.000139	0.00146	CcSEcCtD
Naproxen—Hallucination—Temozolomide—brain cancer	0.000139	0.00145	CcSEcCtD
Naproxen—Pharyngitis—Temozolomide—brain cancer	0.000139	0.00145	CcSEcCtD
Naproxen—Urinary tract disorder—Temozolomide—brain cancer	0.000138	0.00144	CcSEcCtD
Naproxen—Oedema peripheral—Temozolomide—brain cancer	0.000138	0.00144	CcSEcCtD
Naproxen—Connective tissue disorder—Temozolomide—brain cancer	0.000137	0.00143	CcSEcCtD
Naproxen—Urethral disorder—Temozolomide—brain cancer	0.000137	0.00143	CcSEcCtD
Naproxen—Feeling abnormal—Procarbazine—brain cancer	0.000135	0.00141	CcSEcCtD
Naproxen—Eye disorder—Carmustine—brain cancer	0.000135	0.00141	CcSEcCtD
Naproxen—Convulsion—Hydroxyurea—brain cancer	0.000135	0.00141	CcSEcCtD
Naproxen—Visual impairment—Temozolomide—brain cancer	0.000135	0.00141	CcSEcCtD
Naproxen—Gastrointestinal pain—Procarbazine—brain cancer	0.000134	0.0014	CcSEcCtD
Naproxen—SLCO1A2—telencephalon—brain cancer	0.000133	0.0328	CbGeAlD
Naproxen—Pancytopenia—Etoposide—brain cancer	0.000133	0.00139	CcSEcCtD
Naproxen—Erythema multiforme—Temozolomide—brain cancer	0.000132	0.00138	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000132	0.00138	CcSEcCtD
Naproxen—Discomfort—Hydroxyurea—brain cancer	0.000131	0.00137	CcSEcCtD
Naproxen—Eye disorder—Temozolomide—brain cancer	0.000131	0.00136	CcSEcCtD
Naproxen—Urticaria—Procarbazine—brain cancer	0.000131	0.00136	CcSEcCtD
Naproxen—Tinnitus—Temozolomide—brain cancer	0.00013	0.00136	CcSEcCtD
Naproxen—Abdominal pain—Procarbazine—brain cancer	0.00013	0.00136	CcSEcCtD
Naproxen—Body temperature increased—Procarbazine—brain cancer	0.00013	0.00136	CcSEcCtD
Naproxen—Cardiac disorder—Temozolomide—brain cancer	0.00013	0.00135	CcSEcCtD
Naproxen—Arrhythmia—Carmustine—brain cancer	0.000129	0.00135	CcSEcCtD
Naproxen—Alopecia—Carmustine—brain cancer	0.000128	0.00133	CcSEcCtD
Naproxen—Oedema—Hydroxyurea—brain cancer	0.000127	0.00133	CcSEcCtD
Naproxen—Angiopathy—Temozolomide—brain cancer	0.000127	0.00132	CcSEcCtD
Naproxen—Mental disorder—Carmustine—brain cancer	0.000127	0.00132	CcSEcCtD
Naproxen—Infection—Hydroxyurea—brain cancer	0.000126	0.00132	CcSEcCtD
Naproxen—Immune system disorder—Temozolomide—brain cancer	0.000126	0.00132	CcSEcCtD
Naproxen—Mediastinal disorder—Temozolomide—brain cancer	0.000126	0.00132	CcSEcCtD
Naproxen—Erythema—Carmustine—brain cancer	0.000126	0.00131	CcSEcCtD
Naproxen—Malnutrition—Carmustine—brain cancer	0.000126	0.00131	CcSEcCtD
Naproxen—Chills—Temozolomide—brain cancer	0.000125	0.00131	CcSEcCtD
Naproxen—Pneumonia—Etoposide—brain cancer	0.000125	0.00131	CcSEcCtD
Naproxen—Nervous system disorder—Hydroxyurea—brain cancer	0.000125	0.0013	CcSEcCtD
Naproxen—Thrombocytopenia—Hydroxyurea—brain cancer	0.000124	0.0013	CcSEcCtD
Naproxen—UGT1A1—endocrine gland—brain cancer	0.000124	0.0306	CbGeAlD
Naproxen—Stevens-Johnson syndrome—Etoposide—brain cancer	0.000124	0.00129	CcSEcCtD
Naproxen—Alopecia—Temozolomide—brain cancer	0.000124	0.00129	CcSEcCtD
Naproxen—Skin disorder—Hydroxyurea—brain cancer	0.000124	0.00129	CcSEcCtD
Naproxen—Acute coronary syndrome—Etoposide—brain cancer	0.000123	0.00128	CcSEcCtD
Naproxen—Renal failure—Etoposide—brain cancer	0.000123	0.00128	CcSEcCtD
Naproxen—Mental disorder—Temozolomide—brain cancer	0.000122	0.00128	CcSEcCtD
Naproxen—UGT1A1—Aryl Hydrocarbon Receptor Pathway—HES1—brain cancer	0.000122	0.0073	CbGpPWpGaD
Naproxen—Myocardial infarction—Etoposide—brain cancer	0.000122	0.00128	CcSEcCtD
Naproxen—Neuropathy peripheral—Etoposide—brain cancer	0.000122	0.00128	CcSEcCtD
Naproxen—Malnutrition—Temozolomide—brain cancer	0.000122	0.00127	CcSEcCtD
Naproxen—Erythema—Temozolomide—brain cancer	0.000122	0.00127	CcSEcCtD
Naproxen—Stomatitis—Etoposide—brain cancer	0.000121	0.00127	CcSEcCtD
Naproxen—Jaundice—Etoposide—brain cancer	0.000121	0.00127	CcSEcCtD
Naproxen—Anorexia—Hydroxyurea—brain cancer	0.000121	0.00127	CcSEcCtD
Naproxen—Hypersensitivity—Procarbazine—brain cancer	0.000121	0.00126	CcSEcCtD
Naproxen—Vision blurred—Carmustine—brain cancer	0.000119	0.00124	CcSEcCtD
Naproxen—UGT1A1—Biological oxidations—CYP2C9—brain cancer	0.000119	0.00708	CbGpPWpGaD
Naproxen—AKR1C3—cerebellum—brain cancer	0.000118	0.0292	CbGeAlD
Naproxen—Tremor—Carmustine—brain cancer	0.000118	0.00123	CcSEcCtD
Naproxen—Asthenia—Procarbazine—brain cancer	0.000118	0.00123	CcSEcCtD
Naproxen—Hepatobiliary disease—Etoposide—brain cancer	0.000118	0.00123	CcSEcCtD
Naproxen—CYP2C8—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000118	0.00702	CbGpPWpGaD
Naproxen—UGT1A1—Metapathway biotransformation—CYP2C9—brain cancer	0.000117	0.00698	CbGpPWpGaD
Naproxen—CYP1A2—Arachidonic acid metabolism—CYP2C9—brain cancer	0.000117	0.00696	CbGpPWpGaD
Naproxen—Anaemia—Carmustine—brain cancer	0.000116	0.00122	CcSEcCtD
Naproxen—Agranulocytosis—Etoposide—brain cancer	0.000116	0.00121	CcSEcCtD
Naproxen—Pruritus—Procarbazine—brain cancer	0.000116	0.00121	CcSEcCtD
Naproxen—Vision blurred—Temozolomide—brain cancer	0.000115	0.0012	CcSEcCtD
Naproxen—Tremor—Temozolomide—brain cancer	0.000114	0.00119	CcSEcCtD
Naproxen—Dyspnoea—Hydroxyurea—brain cancer	0.000113	0.00118	CcSEcCtD
Naproxen—Somnolence—Hydroxyurea—brain cancer	0.000113	0.00118	CcSEcCtD
Naproxen—Ill-defined disorder—Temozolomide—brain cancer	0.000113	0.00118	CcSEcCtD
Naproxen—Leukopenia—Carmustine—brain cancer	0.000113	0.00118	CcSEcCtD
Naproxen—Anaemia—Temozolomide—brain cancer	0.000112	0.00117	CcSEcCtD
Naproxen—Diarrhoea—Procarbazine—brain cancer	0.000112	0.00117	CcSEcCtD
Naproxen—Dyspepsia—Hydroxyurea—brain cancer	0.000112	0.00117	CcSEcCtD
Naproxen—Angioedema—Temozolomide—brain cancer	0.000111	0.00116	CcSEcCtD
Naproxen—Decreased appetite—Hydroxyurea—brain cancer	0.000111	0.00115	CcSEcCtD
Naproxen—Urinary tract disorder—Etoposide—brain cancer	0.00011	0.00115	CcSEcCtD
Naproxen—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.00011	0.00115	CcSEcCtD
Naproxen—Malaise—Temozolomide—brain cancer	0.00011	0.00115	CcSEcCtD
Naproxen—Urethral disorder—Etoposide—brain cancer	0.00011	0.00114	CcSEcCtD
Naproxen—Fatigue—Hydroxyurea—brain cancer	0.00011	0.00114	CcSEcCtD
Naproxen—Vertigo—Temozolomide—brain cancer	0.000109	0.00114	CcSEcCtD
Naproxen—Convulsion—Carmustine—brain cancer	0.000109	0.00114	CcSEcCtD
Naproxen—Leukopenia—Temozolomide—brain cancer	0.000109	0.00114	CcSEcCtD
Naproxen—Hypertension—Carmustine—brain cancer	0.000109	0.00114	CcSEcCtD
Naproxen—Constipation—Hydroxyurea—brain cancer	0.000109	0.00114	CcSEcCtD
Naproxen—Pain—Hydroxyurea—brain cancer	0.000109	0.00114	CcSEcCtD
Naproxen—Dizziness—Procarbazine—brain cancer	0.000109	0.00113	CcSEcCtD
Naproxen—Palpitations—Temozolomide—brain cancer	0.000108	0.00112	CcSEcCtD
Naproxen—Myalgia—Carmustine—brain cancer	0.000107	0.00112	CcSEcCtD
Naproxen—Chest pain—Carmustine—brain cancer	0.000107	0.00112	CcSEcCtD
Naproxen—Anxiety—Carmustine—brain cancer	0.000107	0.00112	CcSEcCtD
Naproxen—Cough—Temozolomide—brain cancer	0.000106	0.00111	CcSEcCtD
Naproxen—Erythema multiforme—Etoposide—brain cancer	0.000106	0.0011	CcSEcCtD
Naproxen—Convulsion—Temozolomide—brain cancer	0.000105	0.0011	CcSEcCtD
Naproxen—Hypertension—Temozolomide—brain cancer	0.000105	0.0011	CcSEcCtD
Naproxen—Feeling abnormal—Hydroxyurea—brain cancer	0.000105	0.00109	CcSEcCtD
Naproxen—Eye disorder—Etoposide—brain cancer	0.000105	0.00109	CcSEcCtD
Naproxen—Vomiting—Procarbazine—brain cancer	0.000104	0.00109	CcSEcCtD
Naproxen—SLCO1A2—medulla oblongata—brain cancer	0.000104	0.0258	CbGeAlD
Naproxen—Cardiac disorder—Etoposide—brain cancer	0.000104	0.00108	CcSEcCtD
Naproxen—Confusional state—Carmustine—brain cancer	0.000104	0.00108	CcSEcCtD
Naproxen—Myalgia—Temozolomide—brain cancer	0.000104	0.00108	CcSEcCtD
Naproxen—Arthralgia—Temozolomide—brain cancer	0.000104	0.00108	CcSEcCtD
Naproxen—Rash—Procarbazine—brain cancer	0.000104	0.00108	CcSEcCtD
Naproxen—Dermatitis—Procarbazine—brain cancer	0.000103	0.00108	CcSEcCtD
Naproxen—Anxiety—Temozolomide—brain cancer	0.000103	0.00108	CcSEcCtD
Naproxen—Headache—Procarbazine—brain cancer	0.000103	0.00107	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000103	0.00107	CcSEcCtD
Naproxen—Oedema—Carmustine—brain cancer	0.000103	0.00107	CcSEcCtD
Naproxen—Discomfort—Temozolomide—brain cancer	0.000102	0.00107	CcSEcCtD
Naproxen—Infection—Carmustine—brain cancer	0.000102	0.00107	CcSEcCtD
Naproxen—Angiopathy—Etoposide—brain cancer	0.000102	0.00106	CcSEcCtD
Naproxen—Dry mouth—Temozolomide—brain cancer	0.000101	0.00106	CcSEcCtD
Naproxen—Immune system disorder—Etoposide—brain cancer	0.000101	0.00105	CcSEcCtD
Naproxen—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000101	0.00602	CbGpPWpGaD
Naproxen—Mediastinal disorder—Etoposide—brain cancer	0.000101	0.00105	CcSEcCtD
Naproxen—Thrombocytopenia—Carmustine—brain cancer	0.000101	0.00105	CcSEcCtD
Naproxen—Body temperature increased—Hydroxyurea—brain cancer	0.000101	0.00105	CcSEcCtD
Naproxen—Chills—Etoposide—brain cancer	0.0001	0.00105	CcSEcCtD
Naproxen—Tachycardia—Carmustine—brain cancer	0.0001	0.00105	CcSEcCtD
Naproxen—Confusional state—Temozolomide—brain cancer	0.0001	0.00105	CcSEcCtD
Naproxen—CYP1A2—Oxidation by Cytochrome P450—CYP2C9—brain cancer	9.96e-05	0.00594	CbGpPWpGaD
Naproxen—Anaphylactic shock—Temozolomide—brain cancer	9.93e-05	0.00104	CcSEcCtD
Naproxen—Oedema—Temozolomide—brain cancer	9.93e-05	0.00104	CcSEcCtD
Naproxen—Alopecia—Etoposide—brain cancer	9.89e-05	0.00103	CcSEcCtD
Naproxen—Infection—Temozolomide—brain cancer	9.87e-05	0.00103	CcSEcCtD
Naproxen—Anorexia—Carmustine—brain cancer	9.8e-05	0.00102	CcSEcCtD
Naproxen—Nausea—Procarbazine—brain cancer	9.76e-05	0.00102	CcSEcCtD
Naproxen—Nervous system disorder—Temozolomide—brain cancer	9.74e-05	0.00102	CcSEcCtD
Naproxen—Thrombocytopenia—Temozolomide—brain cancer	9.73e-05	0.00102	CcSEcCtD
Naproxen—PTGS1—Biological oxidations—CYP2C9—brain cancer	9.67e-05	0.00577	CbGpPWpGaD
Naproxen—Skin disorder—Temozolomide—brain cancer	9.65e-05	0.00101	CcSEcCtD
Naproxen—Hypotension—Carmustine—brain cancer	9.61e-05	0.001	CcSEcCtD
Naproxen—Hyperhidrosis—Temozolomide—brain cancer	9.6e-05	0.001	CcSEcCtD
Naproxen—AKR1C3—brain—brain cancer	9.6e-05	0.0237	CbGeAlD
Naproxen—SLC22A6—brain—brain cancer	9.56e-05	0.0236	CbGeAlD
Naproxen—SLCO1A2—midbrain—brain cancer	9.54e-05	0.0236	CbGeAlD
Naproxen—Anorexia—Temozolomide—brain cancer	9.47e-05	0.000988	CcSEcCtD
Naproxen—Hypersensitivity—Hydroxyurea—brain cancer	9.37e-05	0.000978	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Carmustine—brain cancer	9.37e-05	0.000978	CcSEcCtD
Naproxen—Muscle spasms—Etoposide—brain cancer	9.36e-05	0.000977	CcSEcCtD
Naproxen—SLCO1A2—spinal cord—brain cancer	9.3e-05	0.023	CbGeAlD
Naproxen—Insomnia—Carmustine—brain cancer	9.3e-05	0.00097	CcSEcCtD
Naproxen—Paraesthesia—Carmustine—brain cancer	9.23e-05	0.000964	CcSEcCtD
Naproxen—Dyspnoea—Carmustine—brain cancer	9.16e-05	0.000957	CcSEcCtD
Naproxen—Somnolence—Carmustine—brain cancer	9.14e-05	0.000954	CcSEcCtD
Naproxen—Asthenia—Hydroxyurea—brain cancer	9.12e-05	0.000952	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Temozolomide—brain cancer	9.05e-05	0.000945	CcSEcCtD
Naproxen—Ill-defined disorder—Etoposide—brain cancer	9.04e-05	0.000943	CcSEcCtD
Naproxen—Anaemia—Etoposide—brain cancer	9e-05	0.00094	CcSEcCtD
Naproxen—Insomnia—Temozolomide—brain cancer	8.98e-05	0.000938	CcSEcCtD
Naproxen—Decreased appetite—Carmustine—brain cancer	8.94e-05	0.000933	CcSEcCtD
Naproxen—Paraesthesia—Temozolomide—brain cancer	8.92e-05	0.000931	CcSEcCtD
Naproxen—Gastrointestinal disorder—Carmustine—brain cancer	8.87e-05	0.000926	CcSEcCtD
Naproxen—Dyspnoea—Temozolomide—brain cancer	8.86e-05	0.000924	CcSEcCtD
Naproxen—Somnolence—Temozolomide—brain cancer	8.83e-05	0.000922	CcSEcCtD
Naproxen—Constipation—Carmustine—brain cancer	8.79e-05	0.000918	CcSEcCtD
Naproxen—Pain—Carmustine—brain cancer	8.79e-05	0.000918	CcSEcCtD
Naproxen—Malaise—Etoposide—brain cancer	8.78e-05	0.000917	CcSEcCtD
Naproxen—Vertigo—Etoposide—brain cancer	8.75e-05	0.000913	CcSEcCtD
Naproxen—Dyspepsia—Temozolomide—brain cancer	8.74e-05	0.000913	CcSEcCtD
Naproxen—Leukopenia—Etoposide—brain cancer	8.72e-05	0.00091	CcSEcCtD
Naproxen—Diarrhoea—Hydroxyurea—brain cancer	8.7e-05	0.000908	CcSEcCtD
Naproxen—Decreased appetite—Temozolomide—brain cancer	8.64e-05	0.000901	CcSEcCtD
Naproxen—Gastrointestinal disorder—Temozolomide—brain cancer	8.58e-05	0.000895	CcSEcCtD
Naproxen—Fatigue—Temozolomide—brain cancer	8.56e-05	0.000894	CcSEcCtD
Naproxen—Loss of consciousness—Etoposide—brain cancer	8.56e-05	0.000894	CcSEcCtD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	8.53e-05	0.00509	CbGpPWpGaD
Naproxen—Cough—Etoposide—brain cancer	8.5e-05	0.000887	CcSEcCtD
Naproxen—Constipation—Temozolomide—brain cancer	8.49e-05	0.000887	CcSEcCtD
Naproxen—Pain—Temozolomide—brain cancer	8.49e-05	0.000887	CcSEcCtD
Naproxen—Feeling abnormal—Carmustine—brain cancer	8.47e-05	0.000884	CcSEcCtD
Naproxen—Convulsion—Etoposide—brain cancer	8.44e-05	0.000881	CcSEcCtD
Naproxen—Hypertension—Etoposide—brain cancer	8.41e-05	0.000878	CcSEcCtD
Naproxen—Dizziness—Hydroxyurea—brain cancer	8.41e-05	0.000878	CcSEcCtD
Naproxen—Gastrointestinal pain—Carmustine—brain cancer	8.41e-05	0.000877	CcSEcCtD
Naproxen—SLCO1A2—endocrine gland—brain cancer	8.38e-05	0.0207	CbGeAlD
Naproxen—Chest pain—Etoposide—brain cancer	8.29e-05	0.000866	CcSEcCtD
Naproxen—SLCO1A2—head—brain cancer	8.27e-05	0.0204	CbGeAlD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	8.23e-05	0.00086	CcSEcCtD
Naproxen—Discomfort—Etoposide—brain cancer	8.19e-05	0.000855	CcSEcCtD
Naproxen—Feeling abnormal—Temozolomide—brain cancer	8.19e-05	0.000854	CcSEcCtD
Naproxen—CYP1A2—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	8.18e-05	0.00488	CbGpPWpGaD
Naproxen—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—brain cancer	8.14e-05	0.00485	CbGpPWpGaD
Naproxen—Abdominal pain—Carmustine—brain cancer	8.13e-05	0.000848	CcSEcCtD
Naproxen—Body temperature increased—Carmustine—brain cancer	8.13e-05	0.000848	CcSEcCtD
Naproxen—Gastrointestinal pain—Temozolomide—brain cancer	8.12e-05	0.000848	CcSEcCtD
Naproxen—Vomiting—Hydroxyurea—brain cancer	8.08e-05	0.000844	CcSEcCtD
Naproxen—Rash—Hydroxyurea—brain cancer	8.02e-05	0.000837	CcSEcCtD
Naproxen—Confusional state—Etoposide—brain cancer	8.01e-05	0.000837	CcSEcCtD
Naproxen—Dermatitis—Hydroxyurea—brain cancer	8.01e-05	0.000836	CcSEcCtD
Naproxen—Headache—Hydroxyurea—brain cancer	7.97e-05	0.000832	CcSEcCtD
Naproxen—Anaphylactic shock—Etoposide—brain cancer	7.95e-05	0.00083	CcSEcCtD
Naproxen—Infection—Etoposide—brain cancer	7.9e-05	0.000824	CcSEcCtD
Naproxen—Urticaria—Temozolomide—brain cancer	7.89e-05	0.000824	CcSEcCtD
Naproxen—Abdominal pain—Temozolomide—brain cancer	7.85e-05	0.00082	CcSEcCtD
Naproxen—Body temperature increased—Temozolomide—brain cancer	7.85e-05	0.00082	CcSEcCtD
Naproxen—Thrombocytopenia—Etoposide—brain cancer	7.78e-05	0.000812	CcSEcCtD
Naproxen—Tachycardia—Etoposide—brain cancer	7.76e-05	0.00081	CcSEcCtD
Naproxen—Skin disorder—Etoposide—brain cancer	7.72e-05	0.000806	CcSEcCtD
Naproxen—Hyperhidrosis—Etoposide—brain cancer	7.68e-05	0.000802	CcSEcCtD
Naproxen—PTGS2—Spinal Cord Injury—GFAP—brain cancer	7.59e-05	0.00453	CbGpPWpGaD
Naproxen—Anorexia—Etoposide—brain cancer	7.58e-05	0.000791	CcSEcCtD
Naproxen—Hypersensitivity—Carmustine—brain cancer	7.57e-05	0.000791	CcSEcCtD
Naproxen—CYP2C8—pituitary gland—brain cancer	7.55e-05	0.0187	CbGeAlD
Naproxen—Nausea—Hydroxyurea—brain cancer	7.55e-05	0.000788	CcSEcCtD
Naproxen—SLCO1A2—central nervous system—brain cancer	7.55e-05	0.0187	CbGeAlD
Naproxen—PTGS1—telencephalon—brain cancer	7.52e-05	0.0186	CbGeAlD
Naproxen—Hypotension—Etoposide—brain cancer	7.43e-05	0.000775	CcSEcCtD
Naproxen—SLCO1A2—cerebellum—brain cancer	7.38e-05	0.0182	CbGeAlD
Naproxen—Asthenia—Carmustine—brain cancer	7.38e-05	0.00077	CcSEcCtD
Naproxen—Hypersensitivity—Temozolomide—brain cancer	7.32e-05	0.000764	CcSEcCtD
Naproxen—PTGS2—telencephalon—brain cancer	7.19e-05	0.0178	CbGeAlD
Naproxen—Paraesthesia—Etoposide—brain cancer	7.14e-05	0.000745	CcSEcCtD
Naproxen—Asthenia—Temozolomide—brain cancer	7.13e-05	0.000744	CcSEcCtD
Naproxen—PTGS2—S1P1 pathway—VEGFA—brain cancer	7.09e-05	0.00423	CbGpPWpGaD
Naproxen—Dyspnoea—Etoposide—brain cancer	7.09e-05	0.00074	CcSEcCtD
Naproxen—Somnolence—Etoposide—brain cancer	7.07e-05	0.000738	CcSEcCtD
Naproxen—Diarrhoea—Carmustine—brain cancer	7.03e-05	0.000734	CcSEcCtD
Naproxen—Pruritus—Temozolomide—brain cancer	7.03e-05	0.000734	CcSEcCtD
Naproxen—Decreased appetite—Etoposide—brain cancer	6.91e-05	0.000721	CcSEcCtD
Naproxen—Gastrointestinal disorder—Etoposide—brain cancer	6.86e-05	0.000716	CcSEcCtD
Naproxen—Fatigue—Etoposide—brain cancer	6.85e-05	0.000715	CcSEcCtD
Naproxen—Dizziness—Carmustine—brain cancer	6.8e-05	0.00071	CcSEcCtD
Naproxen—Constipation—Etoposide—brain cancer	6.8e-05	0.00071	CcSEcCtD
Naproxen—Pain—Etoposide—brain cancer	6.8e-05	0.00071	CcSEcCtD
Naproxen—Diarrhoea—Temozolomide—brain cancer	6.8e-05	0.000709	CcSEcCtD
Naproxen—AKR1C3—Disease—DTX2—brain cancer	6.72e-05	0.00401	CbGpPWpGaD
Naproxen—PTGS2—C-MYB transcription factor network—CDK6—brain cancer	6.65e-05	0.00397	CbGpPWpGaD
Naproxen—Dizziness—Temozolomide—brain cancer	6.57e-05	0.000686	CcSEcCtD
Naproxen—Feeling abnormal—Etoposide—brain cancer	6.55e-05	0.000684	CcSEcCtD
Naproxen—Vomiting—Carmustine—brain cancer	6.54e-05	0.000682	CcSEcCtD
Naproxen—Gastrointestinal pain—Etoposide—brain cancer	6.5e-05	0.000679	CcSEcCtD
Naproxen—Rash—Carmustine—brain cancer	6.48e-05	0.000677	CcSEcCtD
Naproxen—Dermatitis—Carmustine—brain cancer	6.48e-05	0.000676	CcSEcCtD
Naproxen—Headache—Carmustine—brain cancer	6.44e-05	0.000672	CcSEcCtD
Naproxen—ALB—Platelet activation, signaling and aggregation—MPL—brain cancer	6.4e-05	0.00382	CbGpPWpGaD
Naproxen—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—brain cancer	6.36e-05	0.00379	CbGpPWpGaD
Naproxen—Vomiting—Temozolomide—brain cancer	6.32e-05	0.000659	CcSEcCtD
Naproxen—Urticaria—Etoposide—brain cancer	6.31e-05	0.000659	CcSEcCtD
Naproxen—Body temperature increased—Etoposide—brain cancer	6.28e-05	0.000656	CcSEcCtD
Naproxen—Abdominal pain—Etoposide—brain cancer	6.28e-05	0.000656	CcSEcCtD
Naproxen—Rash—Temozolomide—brain cancer	6.26e-05	0.000654	CcSEcCtD
Naproxen—Dermatitis—Temozolomide—brain cancer	6.26e-05	0.000653	CcSEcCtD
Naproxen—CYP2C8—Biological oxidations—CYP2C9—brain cancer	6.25e-05	0.00373	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—IDH1—brain cancer	6.24e-05	0.00372	CbGpPWpGaD
Naproxen—Headache—Temozolomide—brain cancer	6.22e-05	0.00065	CcSEcCtD
Naproxen—CYP2C8—Metapathway biotransformation—CYP2C9—brain cancer	6.16e-05	0.00368	CbGpPWpGaD
Naproxen—PTGS1—pituitary gland—brain cancer	6.13e-05	0.0151	CbGeAlD
Naproxen—Nausea—Carmustine—brain cancer	6.11e-05	0.000637	CcSEcCtD
Naproxen—SLCO1A2—brain—brain cancer	5.99e-05	0.0148	CbGeAlD
Naproxen—ALB—brain—brain cancer	5.96e-05	0.0147	CbGeAlD
Naproxen—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—brain cancer	5.95e-05	0.00355	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—SOD2—brain cancer	5.93e-05	0.00353	CbGpPWpGaD
Naproxen—Nausea—Temozolomide—brain cancer	5.9e-05	0.000616	CcSEcCtD
Naproxen—ALB—Vitamin B12 Metabolism—SOD2—brain cancer	5.89e-05	0.00351	CbGpPWpGaD
Naproxen—Hypersensitivity—Etoposide—brain cancer	5.86e-05	0.000611	CcSEcCtD
Naproxen—PTGS2—pituitary gland—brain cancer	5.86e-05	0.0145	CbGeAlD
Naproxen—CYP2C8—endocrine gland—brain cancer	5.85e-05	0.0145	CbGeAlD
Naproxen—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—brain cancer	5.81e-05	0.00347	CbGpPWpGaD
Naproxen—Asthenia—Etoposide—brain cancer	5.7e-05	0.000595	CcSEcCtD
Naproxen—PTGS2—medulla oblongata—brain cancer	5.65e-05	0.014	CbGeAlD
Naproxen—Pruritus—Etoposide—brain cancer	5.62e-05	0.000587	CcSEcCtD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—S100A10—brain cancer	5.6e-05	0.00334	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—OR14C36—brain cancer	5.53e-05	0.0033	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—OR4C12—brain cancer	5.53e-05	0.0033	CbGpPWpGaD
Naproxen—CYP1A2—endocrine gland—brain cancer	5.48e-05	0.0135	CbGeAlD
Naproxen—Diarrhoea—Etoposide—brain cancer	5.44e-05	0.000568	CcSEcCtD
Naproxen—CYP1A2—Estrogen Receptor Pathway—STAT3—brain cancer	5.39e-05	0.00321	CbGpPWpGaD
Naproxen—PTGS1—spinal cord—brain cancer	5.27e-05	0.013	CbGeAlD
Naproxen—SLC22A6—Transmembrane transport of small molecules—S100A10—brain cancer	5.27e-05	0.00314	CbGpPWpGaD
Naproxen—Dizziness—Etoposide—brain cancer	5.26e-05	0.000549	CcSEcCtD
Naproxen—CYP2C9—endocrine gland—brain cancer	5.2e-05	0.0129	CbGeAlD
Naproxen—PTGS2—midbrain—brain cancer	5.16e-05	0.0128	CbGeAlD
Naproxen—Vomiting—Etoposide—brain cancer	5.05e-05	0.000528	CcSEcCtD
Naproxen—PTGS2—spinal cord—brain cancer	5.04e-05	0.0125	CbGeAlD
Naproxen—Rash—Etoposide—brain cancer	5.01e-05	0.000523	CcSEcCtD
Naproxen—Dermatitis—Etoposide—brain cancer	5.01e-05	0.000523	CcSEcCtD
Naproxen—Headache—Etoposide—brain cancer	4.98e-05	0.00052	CcSEcCtD
Naproxen—AKR1C3—Disease—HES5—brain cancer	4.93e-05	0.00294	CbGpPWpGaD
Naproxen—PTGS2—C-MYB transcription factor network—HES1—brain cancer	4.89e-05	0.00292	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	4.88e-05	0.00291	CbGpPWpGaD
Naproxen—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—brain cancer	4.86e-05	0.0029	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—SOD2—brain cancer	4.79e-05	0.00286	CbGpPWpGaD
Naproxen—PTGS1—endocrine gland—brain cancer	4.75e-05	0.0117	CbGeAlD
Naproxen—Nausea—Etoposide—brain cancer	4.72e-05	0.000493	CcSEcCtD
Naproxen—PTGS2—Selenium Micronutrient Network—SOD2—brain cancer	4.71e-05	0.00281	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—DTX2—brain cancer	4.7e-05	0.00281	CbGpPWpGaD
Naproxen—PTGS1—head—brain cancer	4.69e-05	0.0116	CbGeAlD
Naproxen—PTGS2—Aryl Hydrocarbon Receptor—RELA—brain cancer	4.57e-05	0.00273	CbGpPWpGaD
Naproxen—PTGS2—endocrine gland—brain cancer	4.54e-05	0.0112	CbGeAlD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—HES1—brain cancer	4.48e-05	0.00267	CbGpPWpGaD
Naproxen—PTGS2—head—brain cancer	4.48e-05	0.0111	CbGeAlD
Naproxen—CYP1A2—Biological oxidations—CYP2C9—brain cancer	4.35e-05	0.00259	CbGpPWpGaD
Naproxen—CYP1A2—Metapathway biotransformation—CYP2C9—brain cancer	4.29e-05	0.00256	CbGpPWpGaD
Naproxen—PTGS1—central nervous system—brain cancer	4.28e-05	0.0106	CbGeAlD
Naproxen—CYP2C8—brain—brain cancer	4.19e-05	0.0103	CbGeAlD
Naproxen—PTGS2—central nervous system—brain cancer	4.09e-05	0.0101	CbGeAlD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—SHH—brain cancer	4.08e-05	0.00243	CbGpPWpGaD
Naproxen—PTGS2—cerebellum—brain cancer	4e-05	0.00988	CbGeAlD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—brain cancer	3.87e-05	0.00231	CbGpPWpGaD
Naproxen—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—brain cancer	3.85e-05	0.0023	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—SOD2—brain cancer	3.81e-05	0.00227	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—CYP2C9—brain cancer	3.8e-05	0.00227	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	3.71e-05	0.00222	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—IDH1—brain cancer	3.57e-05	0.00213	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PTCH2—brain cancer	3.57e-05	0.00213	CbGpPWpGaD
Naproxen—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—brain cancer	3.5e-05	0.00209	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—HES5—brain cancer	3.45e-05	0.00206	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—RELA—brain cancer	3.43e-05	0.00204	CbGpPWpGaD
Naproxen—ALB—Vitamin B12 Metabolism—RELA—brain cancer	3.4e-05	0.00203	CbGpPWpGaD
Naproxen—PTGS1—brain—brain cancer	3.4e-05	0.00839	CbGeAlD
Naproxen—AKR1C3—Signaling Pathways—STRADA—brain cancer	3.35e-05	0.002	CbGpPWpGaD
Naproxen—AKR1C3—Disease—IDH1—brain cancer	3.32e-05	0.00198	CbGpPWpGaD
Naproxen—ALB—Hemostasis—MPL—brain cancer	3.3e-05	0.00197	CbGpPWpGaD
Naproxen—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—brain cancer	3.29e-05	0.00196	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—brain cancer	3.27e-05	0.00195	CbGpPWpGaD
Naproxen—PTGS2—brain—brain cancer	3.25e-05	0.00802	CbGeAlD
Naproxen—AKR1C3—Metabolism—BSG—brain cancer	3.23e-05	0.00193	CbGpPWpGaD
Naproxen—PTGS2—Aryl Hydrocarbon Receptor—MYC—brain cancer	3.22e-05	0.00192	CbGpPWpGaD
Naproxen—ALB—Hemostasis—S100A10—brain cancer	3.16e-05	0.00189	CbGpPWpGaD
Naproxen—PTGS2—Aryl Hydrocarbon Receptor—EGFR—brain cancer	3.15e-05	0.00188	CbGpPWpGaD
Naproxen—AKR1C3—Disease—HEY1—brain cancer	3.15e-05	0.00188	CbGpPWpGaD
Naproxen—AKR1C3—Disease—DLL1—brain cancer	3.08e-05	0.00184	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	2.95e-05	0.00176	CbGpPWpGaD
Naproxen—PTGS2—C-MYB transcription factor network—CDKN2A—brain cancer	2.93e-05	0.00175	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—CDK4—brain cancer	2.92e-05	0.00174	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—TRPC6—brain cancer	2.83e-05	0.00169	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—ABR—brain cancer	2.8e-05	0.00167	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—IDH1—brain cancer	2.78e-05	0.00166	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—RELA—brain cancer	2.77e-05	0.00165	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—S100A10—brain cancer	2.74e-05	0.00163	CbGpPWpGaD
Naproxen—PTGS2—Selenium Micronutrient Network—RELA—brain cancer	2.72e-05	0.00162	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—IDH1—brain cancer	2.72e-05	0.00162	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—GLI2—brain cancer	2.7e-05	0.00161	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—brain cancer	2.68e-05	0.0016	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—SIRT1—brain cancer	2.63e-05	0.00157	CbGpPWpGaD
Naproxen—AKR1C3—Disease—SHH—brain cancer	2.62e-05	0.00156	CbGpPWpGaD
Naproxen—AKR1C3—Disease—ENO2—brain cancer	2.62e-05	0.00156	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—brain cancer	2.6e-05	0.00155	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—TRPC6—brain cancer	2.59e-05	0.00154	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—RELA—brain cancer	2.59e-05	0.00154	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—GLI1—brain cancer	2.54e-05	0.00152	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—CYP2C9—brain cancer	2.5e-05	0.00149	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—IL2—brain cancer	2.49e-05	0.00149	CbGpPWpGaD
Naproxen—PTGS2—C-MYB transcription factor network—CCND1—brain cancer	2.48e-05	0.00148	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—TRPC6—brain cancer	2.43e-05	0.00145	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—PDGFRA—brain cancer	2.41e-05	0.00144	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—SUFU—brain cancer	2.41e-05	0.00144	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	2.4e-05	0.00143	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	2.39e-05	0.00142	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—brain cancer	2.33e-05	0.00139	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—GFAP—brain cancer	2.32e-05	0.00139	CbGpPWpGaD
Naproxen—PTGS2—Disease—DTX2—brain cancer	2.32e-05	0.00138	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—brain cancer	2.3e-05	0.00137	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	2.26e-05	0.00135	CbGpPWpGaD
Naproxen—ALB—Hemostasis—BSG—brain cancer	2.23e-05	0.00133	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—HEY1—brain cancer	2.2e-05	0.00131	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—RELA—brain cancer	2.2e-05	0.00131	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—ENO2—brain cancer	2.2e-05	0.00131	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—CYP2C9—brain cancer	2.17e-05	0.0013	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—DLL1—brain cancer	2.16e-05	0.00129	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—IDH1—brain cancer	2.16e-05	0.00129	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—BSG—brain cancer	2.12e-05	0.00127	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—VAV1—brain cancer	2.12e-05	0.00127	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CYP2C9—brain cancer	2.03e-05	0.00121	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—brain cancer	1.99e-05	0.00119	CbGpPWpGaD
Naproxen—PTGS2—C-MYB transcription factor network—MYC—brain cancer	1.99e-05	0.00119	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—brain cancer	1.98e-05	0.00118	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—IL2—brain cancer	1.94e-05	0.00116	CbGpPWpGaD
Naproxen—AKR1C3—Disease—VAV1—brain cancer	1.89e-05	0.00113	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—CCND1—brain cancer	1.89e-05	0.00113	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—APC—brain cancer	1.87e-05	0.00112	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—BSG—brain cancer	1.85e-05	0.0011	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—SHH—brain cancer	1.84e-05	0.0011	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—IDH1—brain cancer	1.83e-05	0.00109	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—MYC—brain cancer	1.82e-05	0.00109	CbGpPWpGaD
Naproxen—ALB—Platelet degranulation—VEGFA—brain cancer	1.82e-05	0.00108	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—brain cancer	1.78e-05	0.00106	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—brain cancer	1.78e-05	0.00106	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TRPC6—brain cancer	1.77e-05	0.00106	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—IDH1—brain cancer	1.75e-05	0.00105	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—IDH1—brain cancer	1.74e-05	0.00104	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PTCH1—brain cancer	1.74e-05	0.00104	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—SMO—brain cancer	1.74e-05	0.00104	CbGpPWpGaD
Naproxen—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—brain cancer	1.73e-05	0.00103	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—BSG—brain cancer	1.73e-05	0.00103	CbGpPWpGaD
Naproxen—PTGS2—Disease—HES5—brain cancer	1.7e-05	0.00102	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	1.67e-05	0.000995	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CYP2C9—brain cancer	1.65e-05	0.000987	CbGpPWpGaD
Naproxen—AKR1C3—Disease—HES1—brain cancer	1.63e-05	0.000972	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—TP53—brain cancer	1.6e-05	0.000955	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—IDH1—brain cancer	1.59e-05	0.000948	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PDGFRA—brain cancer	1.55e-05	0.000925	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—MYC—brain cancer	1.51e-05	0.000903	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—IDH1—brain cancer	1.48e-05	0.000885	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—EGFR—brain cancer	1.48e-05	0.000883	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TRPC6—brain cancer	1.46e-05	0.000871	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	1.45e-05	0.000867	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—ENO2—brain cancer	1.44e-05	0.000861	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—IDH1—brain cancer	1.43e-05	0.000852	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—BSG—brain cancer	1.41e-05	0.000839	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—NOTCH2—brain cancer	1.39e-05	0.00083	CbGpPWpGaD
Naproxen—AKR1C3—Disease—IRS2—brain cancer	1.36e-05	0.000813	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—PIK3CG—brain cancer	1.35e-05	0.000804	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—VAV1—brain cancer	1.33e-05	0.000791	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CYP2C9—brain cancer	1.31e-05	0.000783	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.29e-05	0.000772	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	1.28e-05	0.000766	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	1.27e-05	0.000759	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—TRPC6—brain cancer	1.26e-05	0.000754	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—ENO2—brain cancer	1.26e-05	0.00075	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—TP53—brain cancer	1.24e-05	0.000742	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—brain cancer	1.22e-05	0.000728	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—IDH1—brain cancer	1.21e-05	0.000721	CbGpPWpGaD
Naproxen—AKR1C3—Disease—APC—brain cancer	1.2e-05	0.000718	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—ENO2—brain cancer	1.17e-05	0.000699	CbGpPWpGaD
Naproxen—PTGS2—Disease—IDH1—brain cancer	1.15e-05	0.000684	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—HES1—brain cancer	1.14e-05	0.000681	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	1.12e-05	0.000668	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—BSG—brain cancer	1.12e-05	0.000666	CbGpPWpGaD
Naproxen—ALB—Hemostasis—VAV1—brain cancer	1.09e-05	0.000653	CbGpPWpGaD
Naproxen—PTGS2—Disease—HEY1—brain cancer	1.09e-05	0.000648	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PDGFRA—brain cancer	1.09e-05	0.000648	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CYP2C9—brain cancer	1.07e-05	0.000637	CbGpPWpGaD
Naproxen—PTGS2—Disease—DLL1—brain cancer	1.07e-05	0.000636	CbGpPWpGaD
Naproxen—ALB—Metabolism—CYP2C9—brain cancer	1.06e-05	0.000634	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—SPP1—brain cancer	1.05e-05	0.000629	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	1.03e-05	0.000614	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	1.01e-05	0.000601	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PIK3CG—brain cancer	1.01e-05	0.000601	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	9.85e-06	0.000587	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—IDH1—brain cancer	9.6e-06	0.000573	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—ENO2—brain cancer	9.56e-06	0.00057	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IRS2—brain cancer	9.54e-06	0.000569	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—IL2—brain cancer	9.49e-06	0.000566	CbGpPWpGaD
Naproxen—AKR1C3—Disease—ERBB2—brain cancer	9.34e-06	0.000557	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—BSG—brain cancer	9.09e-06	0.000542	CbGpPWpGaD
Naproxen—PTGS2—Disease—SHH—brain cancer	9.06e-06	0.000541	CbGpPWpGaD
Naproxen—PTGS2—Disease—ENO2—brain cancer	9.06e-06	0.000541	CbGpPWpGaD
Naproxen—ALB—Metabolism—BSG—brain cancer	9.03e-06	0.000539	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	8.46e-06	0.000505	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PIK3CG—brain cancer	8.43e-06	0.000503	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—APC—brain cancer	8.43e-06	0.000503	CbGpPWpGaD
Naproxen—AKR1C3—Disease—CTNNB1—brain cancer	8.17e-06	0.000487	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—VEGFA—brain cancer	8.06e-06	0.000481	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	7.82e-06	0.000466	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—IDH1—brain cancer	7.81e-06	0.000466	CbGpPWpGaD
Naproxen—ALB—Metabolism—IDH1—brain cancer	7.77e-06	0.000463	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ENO2—brain cancer	7.59e-06	0.000453	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP2C9—brain cancer	7.43e-06	0.000443	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—BSG—brain cancer	7.39e-06	0.000441	CbGpPWpGaD
Naproxen—AKR1C3—Disease—STAT3—brain cancer	7.13e-06	0.000425	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PIK3CG—brain cancer	6.95e-06	0.000414	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PIK3CG—brain cancer	6.62e-06	0.000395	CbGpPWpGaD
Naproxen—AKR1C3—Disease—MYC—brain cancer	6.62e-06	0.000395	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—RELA—brain cancer	6.58e-06	0.000393	CbGpPWpGaD
Naproxen—PTGS2—Disease—VAV1—brain cancer	6.55e-06	0.000391	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—ERBB2—brain cancer	6.54e-06	0.00039	CbGpPWpGaD
Naproxen—AKR1C3—Disease—EGFR—brain cancer	6.48e-06	0.000386	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	6.36e-06	0.000379	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—IDH1—brain cancer	6.36e-06	0.000379	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	6.33e-06	0.000377	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—BSG—brain cancer	6.32e-06	0.000377	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ENO2—brain cancer	6.18e-06	0.000368	CbGpPWpGaD
Naproxen—ALB—Metabolism—ENO2—brain cancer	6.14e-06	0.000366	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IL2—brain cancer	5.93e-06	0.000354	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CCND1—brain cancer	5.78e-06	0.000345	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CG—brain cancer	5.77e-06	0.000344	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CTNNB1—brain cancer	5.72e-06	0.000341	CbGpPWpGaD
Naproxen—PTGS2—Disease—HES1—brain cancer	5.63e-06	0.000336	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—IDH1—brain cancer	5.43e-06	0.000324	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CG—brain cancer	5.38e-06	0.000321	CbGpPWpGaD
Naproxen—PTGS2—Disease—PDGFRA—brain cancer	5.36e-06	0.00032	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	5.18e-06	0.000309	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—VEGFA—brain cancer	5.04e-06	0.000301	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ENO2—brain cancer	5.03e-06	0.0003	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—STAT3—brain cancer	4.99e-06	0.000298	CbGpPWpGaD
Naproxen—ALB—Hemostasis—IL2—brain cancer	4.89e-06	0.000292	CbGpPWpGaD
Naproxen—PTGS2—Disease—IRS2—brain cancer	4.71e-06	0.000281	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MYC—brain cancer	4.64e-06	0.000277	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—EGFR—brain cancer	4.53e-06	0.00027	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	4.42e-06	0.000264	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CG—brain cancer	4.39e-06	0.000262	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ENO2—brain cancer	4.3e-06	0.000256	CbGpPWpGaD
Naproxen—PTGS2—Disease—APC—brain cancer	4.16e-06	0.000248	CbGpPWpGaD
Naproxen—ALB—Hemostasis—VEGFA—brain cancer	4.16e-06	0.000248	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TP53—brain cancer	3.81e-06	0.000227	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CG—brain cancer	3.48e-06	0.000208	CbGpPWpGaD
Naproxen—PTGS2—Disease—ERBB2—brain cancer	3.23e-06	0.000193	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TP53—brain cancer	3.14e-06	0.000187	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CG—brain cancer	2.83e-06	0.000169	CbGpPWpGaD
Naproxen—PTGS2—Disease—CTNNB1—brain cancer	2.82e-06	0.000168	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CG—brain cancer	2.82e-06	0.000168	CbGpPWpGaD
Naproxen—PTGS2—Disease—STAT3—brain cancer	2.46e-06	0.000147	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CG—brain cancer	2.31e-06	0.000138	CbGpPWpGaD
Naproxen—PTGS2—Disease—MYC—brain cancer	2.29e-06	0.000136	CbGpPWpGaD
Naproxen—PTGS2—Disease—EGFR—brain cancer	2.24e-06	0.000133	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CG—brain cancer	1.97e-06	0.000118	CbGpPWpGaD
